Key result
Stopping therapy after achieving remission of proteinuria resulted in sustained remission for 28% of the total cohort, while 29% experienced a relapse, though proteinuria remained less than 0.5 g/day in most cases.
Why the study?
Does stopping combined Aliskiren and Losartan therapy affect the relapse of proteinuria in non-diabetic CKD patients?
Cohort (n=154)
No
Does stopping combined Aliskiren and Losartan therapy affect the relapse of proteinuria in non-diabetic CKD patients?
This study aims to determine the optimal timing for stopping combined aliskiren and losartan therapy in non-diabetic CKD patients by evaluating long-term proteinuria remission and relapse rates.
Supports considering finite 3-year ARB therapy in non-diabetic CKD proteinuria; leaves open need for prospective RCTs to confirm optimal duration and withdrawal safety.
This is a 6 year retrospective analysis of the therapeutic efficacy and safety of Combined Aliskiren (150 mg a day) and Losartan (100 mg a day) in non Diabetic Chronic Kidney Disease (CKD) patients. The objective of this Second (2nd) Phase study was to ascertain the proportion of patients who would remain in remission for the next 3 years and for those who had a relapse of proteinuria after stopping treatment in order to decide when would be an optimum time to stop therapy as well as to ascertain the effects of stopping therapy.
No takes yet. Share an insight, caveat, or question.
Keng-Thye Woo (2017) conducted a cohort in Non-Diabetic Chronic Kidney Disease with Proteinuria (n=154). Stopping therapy (due to remission) vs. Continuing Losartan 100 mg/day (due to continuing proteinuria) was evaluated on Relapse of proteinuria after stopping treatment. Stopping therapy after achieving remission of proteinuria resulted in sustained remission for 28% of the total cohort, while 29% experienced a relapse, though proteinuria remained less than 0.5 g/day in most cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: